MedTrace Logo

Bioequivalence Study for Desloratadine OD Tablets 5 mg Under Fasting Condition

NCT01506050 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2012-01-09

No results posted yet for this study

Summary

This is an open label, randomised, single dose, 2-way crossover, comparative bioequivalence study.

Conditions

  • Healthy

Interventions

DRUG

Desloratadine

Desloratadine ODT 5 mg

Sponsors & Collaborators

  • Dr. Reddy's Laboratories Limited

    lead INDUSTRY

Principal Investigators

  • Antonio R Pizarro, MD · SFBC Anapharm

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-01-31
Completion
2006-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01506050 on ClinicalTrials.gov